



MEN

FIRST CANCER SITE
COLON RECTUM

COLON RECTUM
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

COLON RETTO
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	101421		114827		114827		101421		76634		29106		10289		101421	114827
Person-years ▶	393779		411675		17896		72904		190769		91013		39093		393779	411675
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND COLON RECTUM	7069	0.90	8287	1.01	1218	3.65	1081	0.80	3206	0.87	1870	0.97	912	1.02	-2.02	0.21
HEAD AND NECK	285	0.83	299	0.84	14	0.90	41	0.65	149	0.90	68	0.86	27	0.81	-0.14	-0.14
ORAL CAVITY	68	0.85	72	0.86	4	1.11	15	1.02	34	0.88	14	0.75	5	0.62	-0.03	-0.03
PHARYNX	52	0.75	57	0.78	5	1.57	7	0.54	30	0.88	12	0.76	3	0.45	-0.04	-0.04
LARYNX	165	0.86	170	0.85	5	0.57	19	0.53	85	0.91	42	0.95	19	1.02	-0.07	-0.08
OESOPHAGUS	82	0.89	98	1.02	16	3.92	17	1.03	36	0.82	21	0.97	8	0.82	-0.03	0.00
STOMACH	501	0.88	544	0.91	43	1.70	57	0.57	237	0.88	144	1.05	63	1.00	-0.18	-0.13
COLON RECTUM	468	0.37	936	0.71	468	8.87	96	0.45	262	0.44	62	0.20	48	0.32	-2.03	-0.93
COLON	240	0.27	637	0.70	397	11.04	44	0.30	126	0.31	37	0.17	33	0.32	-1.61	-0.66
RECTUM	228	0.58	299	0.73	71	4.23	52	0.77	136	0.74	25	0.26	15	0.34	-0.42	-0.27
LIVER	264	0.74	355	0.95	91	5.94	46	0.74	104	0.61	76	0.88	38	0.96	-0.24	-0.04
GALLBLADDER	80	0.79	86	0.82	6	1.41	8	0.47	32	0.68	29	1.16	11	0.92	-0.05	-0.05
PANCREAS	189	0.76	200	0.77	11	1.06	37	0.88	71	0.61	52	0.85	29	1.00	-0.15	-0.14
LUNG	1348	0.86	1530	0.93	182	2.66	197	0.71	604	0.81	379	1.00	168	0.98	-0.58	-0.28
SKIN MELANOMA	138	1.15	153	1.22	15	3.08	19	0.95	64	1.14	36	1.21	19	1.33	0.05	0.07
MESOTHELIOMA	37	0.80	41	0.85	4	2.12	5	0.64	21	0.97	9	0.79	2	0.37	-0.02	-0.02
KAPOSI SARCOMA	20	1.06	22	1.12	2	2.43	2	0.61	10	1.13	6	1.33	2	0.92	0.00	0.01
SOFT TISSUE	24	0.79	31	0.97	7	5.44	3	0.57	11	0.77	8	1.07	2	0.57	-0.02	0.00
BONE	4	0.52	4	0.50	0	0.00	0	0.00	1	0.27	2	1.11	1	1.26	-0.01	-0.01
BREAST	17	0.88	20	1.00	3	3.69	3	0.91	7	0.77	5	1.06	2	0.90	-0.01	0.00
PROSTATE	1712	0.94	1942	1.02	230	3.13	250	0.83	748	0.88	486	1.06	228	1.06	-0.28	0.11
TESTIS	11	1.37	13	1.55	2	5.29	1	0.65	6	1.53	3	1.67	1	1.34	0.01	0.01
KIDNEY AND RENAL PELVIS	358	1.31	591	2.07	233	20.36	101	2.16	162	1.25	63	0.94	32	1.04	0.21	0.74
BLADDER AND URINARY TRACT	1013	0.99	1216	1.14	203	4.68	146	0.83	497	1.04	234	0.94	136	1.17	-0.02	0.37
URINARY BLADDER	965	0.99	1159	1.14	194	4.67	144	0.86	476	1.04	222	0.93	123	1.11	-0.03	0.35
URINARY TRACT	48	1.07	57	1.22	9	4.81	2	0.27	21	1.00	12	1.08	13	2.41	0.01	0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	67	0.69	71	0.70	4	0.95	12	0.69	22	0.47	16	0.69	17	1.65	-0.08	-0.07
THYROID	60	1.67	66	1.76	6	3.91	12	1.89	33	1.92	11	1.29	4	1.06	0.06	0.07
HODGKIN LYMPHOMA	12	0.76	16	0.96	4	5.48	4	1.35	3	0.39	5	1.37	0	0.00	-0.01	0.00
NON-HODGKIN LYMPHOMA	218	0.87	262	1.01	44	4.19	37	0.87	96	0.82	54	0.89	31	1.09	-0.08	0.00
MYELOMA	97	0.80	102	0.81	5	0.97	17	0.82	42	0.74	28	0.94	10	0.71	-0.06	-0.06
LEUKAEMIAS	199	0.95	232	1.06	33	3.65	27	0.75	98	1.00	49	0.96	25	1.05	-0.03	0.03
LYMPHOID LEUKAEMIAS	89	0.90	119	1.15	30	6.94	11	0.63	39	0.83	27	1.13	12	1.09	-0.03	0.04
MYELOID LEUKAEMIAS	99	1.04	102	1.03	3	0.75	13	0.81	52	1.18	21	0.90	13	1.17	0.01	0.01
OTHER LEUKAEMIAS	11	0.71	11	0.68	0	0.00	3	1.09	7	0.96	1	0.27	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	333	0.68	393	0.78	60	2.95	39	0.48	152	0.67	86	0.72	56	0.96	-0.39	-0.27

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
COLON RECTUM
COLON RECTUM
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

COLON RETTO
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	89720		101452		101452		89720		67604		28017		11076		89720	101452
Person-years ▶	375841		391664		15823		64370		173550		92079		45842		375841	391664
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND COLON RECTUM	4125	1.04	4780	1.15	655	4.09	619	0.96	1859	1.04	1068	1.05	579	1.07	0.38	1.63
HEAD AND NECK	56	0.96	57	0.93	1	0.42	5	0.53	28	1.06	16	1.08	7	0.88	-0.01	-0.01
ORAL CAVITY	30	0.91	31	0.91	1	0.77	2	0.39	13	0.90	9	1.06	6	1.28	-0.01	-0.01
PHARYNX	11	0.92	11	0.88	0	0.00	2	0.99	6	1.09	3	1.02	0	0.00	0.00	0.00
LARYNX	15	1.08	15	1.04	0	0.00	1	0.43	9	1.42	4	1.16	1	0.56	0.00	0.00
OESOPHAGUS	21	0.85	22	0.86	1	1.01	3	0.77	12	1.10	4	0.63	2	0.57	-0.01	-0.01
STOMACH	311	1.00	336	1.04	25	1.90	31	0.61	144	1.04	75	0.95	61	1.44	0.00	0.03
COLON RECTUM	288	0.37	494	0.62	206	6.71	62	0.51	142	0.42	42	0.21	42	0.39	-1.28	-0.78
COLON	125	0.23	288	0.50	163	7.40	30	0.34	56	0.23	23	0.16	16	0.20	-1.14	-0.74
RECTUM	163	0.76	206	0.93	43	4.95	32	0.93	86	0.90	19	0.35	26	0.90	-0.13	-0.04
LIVER	90	0.67	111	0.79	21	3.89	9	0.42	37	0.62	29	0.84	15	0.79	-0.12	-0.07
GALLBLADDER	61	0.56	75	0.66	14	3.11	7	0.40	29	0.60	10	0.36	15	0.97	-0.13	-0.10
PANCREAS	181	0.88	187	0.87	6	0.75	23	0.73	79	0.88	52	0.96	27	0.87	-0.07	-0.07
LUNG	413	1.37	460	1.47	47	4.04	46	0.98	192	1.44	115	1.47	60	1.38	0.30	0.37
SKIN MELANOMA	90	1.14	105	1.28	15	4.83	14	1.10	33	0.92	31	1.54	12	1.13	0.03	0.06
MESOTHELIOMA	8	0.65	11	0.86	3	6.46	1	0.53	4	0.74	1	0.31	2	1.12	-0.01	0.00
KAPOSI SARCOMA	8	1.15	9	1.25	1	3.55	0	0.00	4	1.32	4	2.24	0	0.00	0.00	0.00
SOFT TISSUE	17	0.89	20	1.01	3	3.96	7	2.29	3	0.35	5	1.03	2	0.75	-0.01	0.00
BONE	4	0.77	5	0.93	1	4.55	1	1.15	1	0.43	2	1.54	0	0.00	0.00	0.00
BREAST	1218	1.10	1405	1.22	187	4.18	203	1.11	552	1.09	314	1.13	149	1.04	0.30	0.65
CERVIX UTERI	62	1.11	81	1.39	19	7.67	8	0.80	33	1.26	15	1.13	6	0.95	0.02	0.06
CORPUS UTERI	267	1.33	314	1.51	47	5.71	28	0.83	119	1.29	76	1.53	44	1.77	0.18	0.27
OVARY	192	1.35	215	1.45	23	3.96	48	2.05	108	1.68	23	0.65	13	0.71	0.13	0.17
KIDNEY AND RENAL PELVIS	146	1.29	262	2.22	116	26.45	33	1.85	68	1.35	32	1.09	13	0.81	0.09	0.37
BLADDER AND URINARY TRACT	235	1.24	283	1.44	48	6.43	46	1.55	94	1.13	55	1.12	40	1.47	0.12	0.22
URINARY BLADDER	214	1.22	259	1.42	45	6.49	44	1.60	84	1.09	51	1.12	35	1.39	0.10	0.20
URINARY TRACT	21	1.52	24	1.68	3	5.67	2	0.96	10	1.68	4	1.11	5	2.38	0.02	0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	55	0.82	57	0.82	2	0.75	3	0.28	26	0.87	16	0.95	10	1.11	-0.03	-0.03
THYROID	91	1.34	95	1.34	4	1.47	11	0.96	46	1.46	23	1.37	11	1.33	0.06	0.06
HODGKIN LYMPHOMA	10	1.00	11	1.06	1	2.31	2	1.15	4	0.86	2	0.83	2	1.70	0.00	0.00
NON-HODGKIN LYMPHOMA	163	0.93	182	1.00	19	2.75	26	0.93	63	0.80	52	1.17	22	0.92	-0.03	0.00
MYELOMA	69	0.81	72	0.81	3	0.88	13	0.96	23	0.61	17	0.78	16	1.36	-0.04	-0.04
LEUKAEMIAS	113	0.92	127	1.00	14	2.82	9	0.46	58	1.07	29	0.92	17	0.99	-0.03	0.00
LYMPHOID LEUKAEMIAS	46	0.85	56	0.99	10	4.48	4	0.45	22	0.91	12	0.87	8	1.09	-0.02	0.00
MYELOID LEUKAEMIAS	54	0.94	57	0.96	3	1.32	5	0.55	30	1.19	12	0.81	7	0.86	-0.01	-0.01
OTHER LEUKAEMIAS	13	1.16	14	1.20	1	2.16	0	0.00	6	1.22	5	1.71	2	1.24	0.00	0.01
OTHER AND ILL DEFINED SITES	244	0.64	278	0.70	34	2.26	42	0.71	99	0.60	70	0.71	33	0.59	-0.36	-0.30

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio